| Date Filed | Type | Description |
| 08/08/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/08/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/31/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/10/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/10/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/12/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/26/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/04/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/11/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/14/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/03/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 12/21/2020 |
4/A
| Atlas Venture Fund IX, L.P. (10% Owner) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Sold 1,700,000 shares
@ $8.1, valued at
$13.8M
|
|
| 12/21/2020 |
4
| Atlas Venture Fund IX, L.P. (10% Owner) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Sold 1,700,000 shares
@ $18.1, valued at
$30.8M
|
|
| 11/12/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/06/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/07/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/11/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/12/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/06/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/13/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/06/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/07/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/31/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/08/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/23/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2018 |
3
| Atlas Venture Fund IX, L.P. (10% Owner) has filed a Form 3 on Surface Oncology, Inc. |
| 04/03/2018 |
4
| Atlas Venture Fund IX, L.P. (10% Owner) has filed a Form 4 on Unum Therapeutics Inc.|
Txns:
| Converted 3,184,446 shares
@ $0
Converted 83,037 shares
@ $0
Bought 94,052 shares
@ $12, valued at
$1.1M
Converted 3,184,446 preferred shares
@ $0
Converted 83,037 preferred shares
@ $0 |
|
| 03/28/2018 |
3
| Atlas Venture Fund IX, L.P. (10% Owner) has filed a Form 3 on Unum Therapeutics, Inc. |
| 02/05/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/03/2017 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/01/2017 |
3
| Atlas Venture Fund IX, L.P. (10% Owner) has filed a Form 3 on Spero Therapeutics, Inc. |
| 07/18/2017 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/11/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/11/2017 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings |
|